| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Allogene Therapeutics, Inc.
13G/A
ALLO · 019770106
|
3.9% |
8/7/2026
Event 6/30/2026
|
||||
| Arie Belldegrun, M.D. | 3.9% | |||||
| Bellco Legacy LLC | 0.2% | |||||
| Bellco Legacy IV LLC | 1.3% | |||||
| Vida Ventures LLC | 0.5% | |||||
| Vida Ventures III, L.P. | 0.5% | |||||
| Vida Ventures III-A, L.P. | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.